Novo Nordisk's (NVO) obesity therapy Wegovy cut adverse kidney-related events by 22% in obese and overweight individuals in a ...
Novo Nordisk, the pharmaceutical company behind Ozempic, has launched a national campaign promoting its injectable ...
Patients taking Novo Nordisk's obesity drug Wegovy maintained an average of 10% weight loss for up to four years, according to a new analysis from the longest clinical trial to date on the treatment.
FAT jabs could be the cancer hope of the future after early studies found they reduce the risk of tumours. The world’s top ...
The rapid rise of weight loss drugs Wegovy and Mounjaro is generating a host of new product lines as companies hope to land ...
La liste des vertus potentielles du Wegovy, le médicament anti-obésité de Novo Nordisk, continue de s’allonger. En mars dernier, la Food and Drug administration (FDA) a approuvé son usage ...
In a letter to Bernie Sanders, Novo Nordisk said it only retains 60% of the list price of either Ozempic or Wegovy ...
Not only has the Danish economy benefited from the success of Ozempic and Wegovy, two more weight-management medications ...
Élargir les indications de son Wegovy est crucial pour Novo Nordisk car cela ouvre la voie au remboursement de son médicament. Hollie Adams / REUTERS Le laboratoire danois explore aussi les ...
Les actions européennes progressent grâce aux valeurs technologiques à l'approche de la décision de la BCE 06/06 RE Novo Nordisk fait face à la concurrence en Chine pour l'ingrédient clé de ...
Les actions européennes progressent grâce aux valeurs technologiques à l'approche de la décision de la BCE 06/06 RE Novo Nordisk fait face à la concurrence en Chine pour l'ingrédient clé de ...